AIRNA develops RNA editing technologies to create medicines for various diseases.
AIRNA has raised $155.0M in total funding. The most recent round was Series B. The last funding was announced in April 2025.
AIRNA's investors include ARCH Venture Partners, RTW Investments, Fast Track Initiative, Inc., Forbion Capital Partners, Ono Venture Investment.
AIRNA is headquartered in Cambridge, United States.
AIRNA develops RNA editing technologies to create medicines for various diseases.
AIRNA is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AIRNA — Funding & Investors." VCBacked, April 1, 2025, https://www.vcbacked.co/company/airna. Accessed July 20, 2026.
VCBacked. (2025). AIRNA — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/airna
{{cite web |title=AIRNA — Funding & Investors |url=https://www.vcbacked.co/company/airna |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated